For two years, the honest answer to a patient with no coverage was: the gray market, or nothing.
That answer has changed, and not because anyone in Washington fixed the underlying problem. It changed because two manufacturers looked at how much revenue was flowing to compounders and decided to compete with them.
What is actually on offer
Self-pay pricing, sold through the manufacturers’ own channels, generally in vial form. Lower cost per month than list, no pharmacy benefit involved, no prior authorization to lose.
What it is not: coverage. There is no insurer, no appeal, no out-of-pocket maximum. If the price moves, it moves for you.
The comparison that actually matters
If you are currently buying compounded semaglutide or tirzepatide, do this arithmetic properly.
| Direct from manufacturer | Compounded | |
|---|---|---|
| FDA-approved product | Yes | No |
| Premarket review for safety and efficacy | Yes | No |
| Dose delivery | Fixed vial dose or pen | Often self-calculated from a vial |
| Recall and adverse event system | Established | Varies enormously by source |
| Price | Below list, above generic-market levels | Usually lower, sometimes far lower |
For a meaningful number of people the gap has narrowed to the point where the risk premium on an unapproved product stops making sense. For others — particularly at higher doses — it has not, and pretending otherwise would be dishonest.
The cheapest defensible option is the one worth finding. Sometimes that is now the approved product, which was not true two years ago.
The vial problem
The direct channels largely supply vials rather than autoinjector pens, because vials are cheaper to make and fill.
A pen delivers a fixed dose when you press it. A vial requires you to draw the correct volume into a syringe. That is a small additional task with a genuinely serious failure mode, and dosing errors have been the most consistently documented harm across the entire self-administered GLP-1 market.
Who should not switch to cash
If you have working coverage with a modest copay, stay where you are. A cash price below list is still far above thirty dollars.
And if you are appealing a denial, do not abandon the appeal because a cash option exists. Winning coverage is worth more over a decade than a discount is over a year, and plans count on people giving up.
Whichever route you take, keep a record of dose, weight and side effects from the start. It is the evidence that makes an appeal winnable later, and it is the thing nobody has when they suddenly need it. Zenday will produce something exportable; so will a spreadsheet you actually maintain.
What this tells you about the market
A price that falls by hundreds of dollars a month, without any change in manufacturing cost, in response to competition from unapproved copies, is informative.
It suggests the previous price was not a reflection of what the drug costs to make. It was a reflection of what the system would bear — and that the moment something forced a genuine market, a large part of it turned out to be negotiable.